Somatropin (HGH 191AA)
Somatropin (HGH 191AA) has Phase 3 RCT-grade clinical evidence for Growth Hormone Deficiency. Off-label / exploratory data exists for 69 additional indications (Growth Hormone Disorder; Pharmacokinetic / healthy volunteer studies). 23 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.
Research Evidence
Evidence shape
Somatropin (HGH 191AA) has Phase 3 RCT-grade clinical evidence for Growth Hormone Deficiency. Off-label / exploratory data exists for 69 additional indications (Growth Hormone Disorder; Pharmacokinetic / healthy volunteer studies). 23 trials were withdrawn or terminated — surfaced below as signal of absence, not omitted.
Anecdotal efficacy
Side effects
Clinical research side effects
Anecdotal side effects
Price
price offers can be sorted by column
Dosing & Protocol
How Somatropin (HGH 191AA) is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
- Frequency
- daily
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
146 completed trials identified; trial dosing not reliably extracted from registry data.
No structured protocol details captured for this tier yet.
- Frequency
- unspecified
- Timing
- unspecified
- Route
- subQ
- Cycle
- unspecified
Anecdotal reporting suggests daily subcutaneous dosing, often split or administered pre-bed. Dosages vary widely based on desired effect, with 200–500mcg commonly reported for anti-aging and general well-being, and 500–1000mcg for performance and body composition.
Peptide Deep Dive
Peptide Deep Dive is not projected for this peptide yet.
Regulatory safety notes
- • Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk •
- • Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment Discontinue treatment if these signs occur •
- • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their firs…
- • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment •
- • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction •
- • Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults) : May occur frequently. Reduce dose…
- • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism •
- • Hypothyroidism: May first become evident or worsen. Monitor thyroid function periodically •
- • • Acute Critical Illness • Children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment – reports of sudden death • Active Malignancy • Hypersensitivity to somatropin or excipients •…
- • patients with: • Acute Critical Illness Treatment with pharmacologic amounts of somatropin is contraindicated in
- • patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1) ]. • P…
- • patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was u…
- • patients with any evidence of progression or recurrence of an underlying intracranial tumor. • Hypersensitivity GENOTROPIN is contraindicated in
- • patients with a known hypersensitivity to somatropin or any of its excipients. The 5 mg and 12 mg presentations of GENOTROPIN lyophilized powder contain m-cresol as a preservative. Systemic hypersensitivity reactions ha…
- • patients with active proliferative or severe non-proliferative diabetic retinopathy. • Closed Epiphyses Somatropin should not be used for growth promotion in pediatric
- • patients with closed epiphyses.
- • Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance dose…
- • Replacement: Should be carefully adjusted (7.2) • Cytochrome P450-Metabolized
- • Drugs: Monitor carefully if used with somatropin (7.3) •
- • Estrogen: Larger doses of somatropin may be required in women (7.4) •
- • Agents: May require adjustment (7.5)
Peptide feedback
0 forum repliesLive community discussion for Somatropin (HGH 191AA), shown here in the site layout and continued on the TVR forum.
No peptide feedback yet
Start the peptide feedback thread on the TVR forum.